Introduction
Multiple sclerosis (MS) is understood to be, at least in part, an autoimmune disease of the central nervous system [1] . The disease causes demyelination, resulting in an array of symptoms, including fatigue, depression, neuromuscular problems, pain, sleep disorders, bowel and bladder problems, vision problems, and sexual dysfunction [2] .
Traditional management of MS often involves frequent selfinjection with disease-modifying treatments (DMTs) [2] . While the use of oral DMTs is increasing, DMTs administered via injection still predominate the first line treatments for MS [3] . Patients with MS face many barriers to adherence to treatment, including cognitive impairment and physical disability impairing their ability to self-inject, perceived lack of efficacy, adverse events, inconvenience, needle phobia, and uncertainty about the injection technique [4, 5] . Patients have reported dissatisfaction with selfinjection; in a recent multinational study, among patients using vials and syringes to self-inject, only 23% reported being "very satisfied" with their current injection method. 5 In another multinational study, 25% of patients were found to be non-adherent to DMTs, with nearly one-third citing injection-related reasons [6] . In the same study, adherent patients reported better quality of life than non-adherent patients [6] . A large database analysis of MS patients in the US found that increasing adherence was associated with a reduced healthcare resource utilization associated with inpatient or emergency room visits, fewer days of work loss, and reduced direct and indirect costs [7] .
There are currently three oral DMTs for MS available in Europe (EU) and the United States (US) -fingolimod, teriflunomide, and dimethyl fumarate, which became available between 2010 and 2014. This research sought to quantify the uptake of oral drugs among patients with MS in EU and the US.
Material and Methods
The study consisted of a multi-center, retrospective chartreview of MS patients inEU [France, Germany, Italy, Spain,the United Kingdom (UK)]and the US, conducted between October and December of 2012 (Q4 2012) and again between April and June 2015 (Q2 2015). Healthcare providers (HCPs) practicing in hospitals or private practices were recruited from a large commercial panel to be geographically representative in each country.
Online HCP panels offer a robust sample of target population for research involving retrospective chart review and cross-sectional survey designs via geo-dispersion sampling (whereby, stakeholders are recruited from a wide selection of clinics/hospitals in a given geography, with each clinic/hospital contributing almost equal number of study samples); this methodology avoids clinic/HCP sampling biases occasionally associated with selection/use of only limited set of institutions, especially in research related to widely prevalent disease(s).
HCPs in this study wereprimarily neurologists (MS nurses were included in the UK) who had been practicing for at 
Results
In 2012, 245 HCPs in EU and 101 HCPs in the US abstracted data for 2479 and 1011 patients, respectively; in 2015, 271 HCPs in EU and 100 HCPs in the US abstracted data for 2724 and 1008 patients, respectively.
Patient demographics and clinical characteristics
At both time points and in both regions, approximately twothirds of the patients were female. The average age was about 40 years. Over half of the patients were considered to have mild MS severity or non-active disease and on average, patients had <1 relapse in last 12 months. The majority of the patients were currently on treatment for MS; specifically 69.8% and 71.9% in EU in 2012 and 2015, respectively, and 78.4% and 80.9% in the US in 2012 and 2015, respectively. (Table 1 ) 
Adoption of Oral DMTs
In 2012 in EU, 11.3% of currently treated patients were on an oral drug (fingolimod), and in the US, 9.2% of currently treated patients were on an oral drug (8.7% on fingolimodand 0.5% on teriflunomide). In 2015, with fingolimod, teriflunomide, and dimethyl fumarateavailable as oral DMTs in both regions, the proportion of patients on an oral DMT increased to 35.6% in EU (p<.01) and 40.0% in US (p<.01). In EU, 14.5% were on fingolimod, 12.8% on dimethyl fumarate, and 8.3% on teriflunomide; in the US, 21.2% were on dimethyl fumarate, 11.2% were on fingolimod, and 7.6% were on teriflunomide. Correspondingly, the market shares of non-oralDMTs decreased during the same time period. (Table 3) Adoption of oral DMTs increased the most in first line therapies in 2015, in comparison to 2012, mainly moving up the line from third line therapies. (Table 3) In 2012, 8.2% of oral DMT users were on their first line DMT therapy (compared to 62.7% of non-oral DMT users, p<.01) in EU; in US, 21.9% of oral DMT users were on their first line DMT therapy (compared to 61.9% of non-oral DMT users, p<.01). In 2015, the proportion of oral DMT users who were on their first line DMT therapy increased to 40.3% in EU (compared to 69.0% of non-oral DMT users, p<.01) and 34.7% in the US (compared to 61.1% of non-oral DMT users, p<.01). 
Discussion
While nearly four in 10 patients studied in 2015 were currently taking an oral DMT for their multiple sclerosis, the market is still dominated by non-oral DMTs. Between 2012 and 2015, largest increase in oral DMTs were observed in first line therapy, with the corresponding decrease in use in third line therapy. Oral administration and patient decision appear to be of greater influence on choice of DMT in the US than in EU. A lower, albeit, exponentially increasing, proportion of patients on their first line DMT were using an oral DMT than patients on a DMT as a subsequent line of therapy, suggesting that oral DMTs may not have been considered the treatment of choice for first line DMT therapy initially (when they are first introduced) either as a function of physicians choice/preference or payer restrictions (tied to formulary position).Patient disease severity, EDSS scores and average number of relapses in last 12months among those on oral DMTs (versus those on nonoral DMTs) in 2012 is reflective of initial use of oral DMTs among patients with severe (or refractory) disease, while 2015 data is indicative of the broader (increasing) adoption of oral DMTs among MS patients as the difference in patient characteristics become less conspicuous.
Treatment guidelines for MS do not offer an algorithmic or "one-size-fits-all" solution, but rather stress the importance of personalized medicine. A 2015 consensus document developed by the Multiple Sclerosis Coalition in the US asserts that multiple complex factors should be taken into account when making treatment decisions, including the mechanism of action and response, contraindications, risk tolerance, route of delivery, side effects, tolerability, and adherence. Thus, the coalition emphasizes that the full range of treatment options should be available to all patients. The coalition also recommends early initiation of a DMT following a diagnosis of relapsing MS, with treatment only changing for medically appropriate reasons, such as suboptimal response, intolerable side effects, poor adherence, or availability of a more appropriate treatment option [8] . The addition of oral DMTs to the armamentarium of treatment options to manage MS patients has been welcomed by HCPs globally, as evident from this research on oral DMT adoption. The choice of specific individual DMTs and establishment of patient profiles that may most benefit from each one may require additional evidence.
The proportion of patients for whom oral administration or patient decision were cited as the reasons for choosing the oral DMT as first line therapy increased in the EU (18.8% vs. 36.1%), while it remained stable in the US (43.8% vs. 40.7%) between 2012 and 2015; citation of these reasons among patients initiating on second line therapy also increased over this time period. Interestingly, among those discontinuing DMTs, "patient refusal" has remained as a key reason for discontinuation in the EU (approx. 20%) and US (approx. 40-50%), indicating an additional dimension of patient influence in treatment decisions. These observed patterns may be reflective of an effort by the HCP community in engaging patients in treatment decisions and offer convenient regimen so as to positively influence patient adherence and long-term outcomes [9] ; however, actual impact of observed treatment patterns on patient behaviour and outcomes warrant further scrutiny.
Restrictions in access to certain DMTs only after failure of first-line therapy may further complicate decision-making in real-world settings [10] .As long-term safety and efficacy data become available for the oral DMTs and comparative effectiveness of treatments becomes known, it may aid therapeutic optimization and prove beneficial for patient outcomes.
Strengths & Limitations
Strengths of this study include the large sample size across countries. It should be noted, however, that the patient management practices reported in this study represent only the practices of the HCPs who participated in this study and may vary from those of non-participating HCPs. Further analysis is warranted to delineate the treatment trends per MS type. All data, including reasons for switching DMTs, are reported by the treating HCPs, and this may vary from patient self-report. Further, careful interpretation of data is warranted in light of the fact that the availability of drugs (especially, the oral DMTs) and the nature of reimbursement hurdles associated with each of them in the studied countries may have influenced the observed trends.
Conclusion
Use of oral DMTs for multiple sclerosis became much more common between 2012 and 2015, due to improved availability and, in part, to patient choice and preference for an oral DMT. Oral DMT adoption increased the most in first line therapy in 2015, moving up from third line therapy positioning predominantly observed in 2012. During the same time period, proportion of patients with higher disease severity and disability level decreased (from 2012 to 2015) among those on oral DMTs. Non-oral DMTs still have a higher market share and oral DMTs are not the treatment of choice yet in first line therapy, despite the likelihood of increased adherence due to the reduced treatment burden. As patients and clinicians become more experienced with oral DMTs over time, future demonstration of long-term outcomes and comparative effectiveness of treatment options may influence appropriate therapy choice to benefit patients.
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